{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:04:55Z","timestamp":1774559095194,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,21]]},"DOI":"10.7759\/cureus.72033","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:24:03Z","timestamp":1729524243000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection"],"prefix":"10.7759","author":[{"given":"Sami H","family":"Alhijazien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan T","family":"Alzayadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majd R","family":"Al Sarhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moayad K","family":"Aldomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal A","family":"Al Shawabkeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad  M","family":"Alsmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031761","article-title":"Historical and molecular perspectives on the presence of Helicobacter pylori in Latin America: a niche to improve gastric cancer risk assessment","volume":"25","author":"Gonz\u00e1lez-Stegmaier R","year":"2024","unstructured":"Gonz\u00e1lez-Stegmaier R, Aguila-Torres P, Villarroel-Esp\u00edndola F. Historical and molecular perspectives on the presence of Helicobacter pylori in Latin America: a niche to improve gastric cancer risk assessment. Int J Mol Sci. 2024, 25:1761. 10.3390\/ijms25031761","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ram.2023.04.003","article-title":"Identification of serologically active Helicobacter pylori antigens related to alterations in serum pepsinogen levels","volume":"55","author":"Gonz\u00e1lez Segovia R","year":"2023","unstructured":"Gonz\u00e1lez Segovia R, Romo Lozano Y, Rodr\u00edguez MG, Monta\u00f1ez Flores AL, Gonz\u00e1lez Mac\u00edas J. Identification of serologically active Helicobacter pylori antigens related to alterations in serum pepsinogen levels. Rev Argent Microbiol. 2023, 55:355-65. 10.1016\/j.ram.2023.04.003","journal-title":"Rev Argent Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner P","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al.. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022, 10.1136\/gutjnl-2022-327745","journal-title":"Gut"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.20524%2Faog.2022.0689","article-title":"Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review","volume":"35","author":"De Francesco V","year":"2022","unstructured":"De Francesco V, Zullo A, Manta R, et al.. Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review. Ann Gastroenterol. 2022 Mar, 35:127-34. 10.20524%2Faog.2022.0689","journal-title":"Ann Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00953-7","article-title":"The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis","volume":"23","author":"Ding YM","year":"2023","unstructured":"Ding YM, Li YY, Liu J, et al.. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med. 2023, 23:1033-43. 10.1007\/s10238-022-00953-7","journal-title":"Clin Exp Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2022.21579","article-title":"High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis","volume":"33","author":"Yin Z","year":"2022","unstructured":"Yin Z, Li J, Huang W, et al.. High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Turk J Gastroenterol. 2022, 33:454-62. 10.5152\/tjg.2022.21579","journal-title":"Turk J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-020-10945-w","article-title":"Helicobacter pylori treatment in the post-antibiotics era-searching for new\u00a0drug targets","volume":"104","author":"Roszczenko-Jasi\u0144ska P","year":"2020","unstructured":"Roszczenko-Jasi\u0144ska P, Wojty\u015b MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new\u00a0drug targets. Appl Microbiol Biotechnol. 2020, 104:9891-905. 10.1007\/s00253-020-10945-w","journal-title":"Appl Microbiol Biotechnol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e20406","article-title":"Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation","volume":"9","author":"Gupta A","year":"2023","unstructured":"Gupta A, Shetty S, Mutalik S, et al.. Treatment of H. pylori infection and gastric ulcer: need for novel pharmaceutical formulation. Heliyon. 2023, 9:e20406. 10.1016\/j.heliyon.2023.e20406","journal-title":"Heliyon"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.06.136","article-title":"Cellulose-based activated carbon\/layered double hydroxide for efficient removal of Clarithromycin residues and efficient role in the treatment of stomach ulcers and acidity problems","volume":"215","author":"Mahgoub SM","year":"2022","unstructured":"Mahgoub SM, Shehata MR, Zaher A, Abo El-Ela FI, Farghali A, Amin RM, Mahmoud R. Cellulose-based activated carbon\/layered double hydroxide for efficient removal of Clarithromycin residues and efficient role in the treatment of stomach ulcers and acidity problems. Int J Biol Macromol. 2022, 215:705-28. 10.1016\/j.ijbiomac.2022.06.136","journal-title":"Int J Biol Macromol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020543","article-title":"Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis","volume":"9","author":"Murata M","year":"2020","unstructured":"Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020, 9:543. 10.3390\/jcm9020543","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.34172\/mejdd.2022.259","article-title":"Addition of nitazoxanide to standard clarithromycin based triple therapy for 2 weeks effectively eradicates treatment-naive Helicobacter pylori infection. A single centre prospective, open-label study","volume":"14","author":"Jha SK","year":"2022","unstructured":"Jha SK, Kumar R, Kumar A, Purkayastha S, Keshri R, Kumar S, Singh AV. Addition of nitazoxanide to standard clarithromycin based triple therapy for 2 weeks effectively eradicates treatment-naive Helicobacter pylori infection. A single centre prospective, open-label study. Middle East J Dig Dis. 2022, 14:77-84. 10.34172\/mejdd.2022.259","journal-title":"Middle East J Dig Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020214","article-title":"Role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for Helicobacter pylori eradication in the clinical setting","volume":"10","author":"Kang S","year":"2021","unstructured":"Kang S, Kim Y, Ahn JY, et al.. Role of antimicrobial susceptibility testing before first-line treatment containing clarithromycin for Helicobacter pylori eradication in the clinical setting. Antibiotics (Basel). 2021, 10:10.3390\/antibiotics10020214","journal-title":"Antibiotics (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.043","article-title":"Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis","volume":"161","author":"Shah SC","year":"2021","unstructured":"Shah SC, Tepler A, Chung CP, et al.. Host genetic determinants associated with Helicobacter pylori eradication treatment failure: a systematic review and meta-analysis. Gastroenterology. 2021, 161:1443-59. 10.1053\/j.gastro.2021.07.043","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8806","article-title":"A note on estimating the Cox-Snell R(2) from a reported C statistic (AUROC) to inform sample size calculations for developing a prediction model with a binary outcome","volume":"40","author":"Riley RD","year":"2021","unstructured":"Riley RD, Van Calster B, Collins GS. A note on estimating the Cox-Snell R(2) from a reported C statistic (AUROC) to inform sample size calculations for developing a prediction model with a binary outcome. Stat Med. 2021, 40:859-64. 10.1002\/sim.8806","journal-title":"Stat Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5009\/gnl20288","article-title":"Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020","volume":"15","author":"Jung HK","year":"2021","unstructured":"Jung HK, Kang SJ, Lee YC, et al.. Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Gut Liver. 2021, 15:168-95. 10.5009\/gnl20288","journal-title":"Gut Liver"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial","volume":"141","author":"Daver NG","year":"2023","unstructured":"Daver NG, Dail M, Garcia JS, et al.. Venetoclax and idasanutlin in relapsed\/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023, 141:1265-76. 10.1182\/blood.2022016362","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/plants13081087","article-title":"Anthriscus sylvestris-noxious weed or sustainable source of bioactive lignans?","volume":"13","author":"Bere\u017eni S","year":"2024","unstructured":"Bere\u017eni S, Mimica-Duki\u0107 N, Domina G, Raimondo FM, Or\u010di\u0107 D. Anthriscus sylvestris-noxious weed or sustainable source of bioactive lignans?. Plants (Basel). 2024, 13:1087. 10.3390\/plants13081087","journal-title":"Plants (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2056015","article-title":"Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure","volume":"16","author":"Shah S","year":"2022","unstructured":"Shah S, Hubscher E, Pelletier C, Jacob R, Vinals L, Yadlapati R. Helicobacter pylori infection treatment in the United States: clinical consequences and costs of eradication treatment failure. Expert Rev Gastroenterol Hepatol. 2022, 16:341-57. 10.1080\/17474124.2022.2056015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.11.012","article-title":"The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance","volume":"44","author":"Huang TH","year":"2021","unstructured":"Huang TH, Yang SC, Tai WC, et al.. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomed J. 2021, 44:S275-81. 10.1016\/j.bj.2020.11.012","journal-title":"Biomed J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/1756284821989177","article-title":"The status and progress of first-line treatment against Helicobacter pylori infection: a review","volume":"14","author":"Liu C","year":"2021","unstructured":"Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol. 2021, 14:10.1177\/1756284821989177","journal-title":"Therap Adv Gastroenterol"},{"key":"ref21","article-title":"Efficacy of triple regimen therapy for H. pylori eradication with and without azithromycin","volume":"36","author":"Tauqeer M","year":"2020","unstructured":"Tauqeer M, Talpur MT, Ahmed T, Aamer N, Shabir S, Yaqoob U . Efficacy of triple regimen therapy for H. pylori eradication with and without azithromycin. Pak J Surg. 2020, 36:152-6.","journal-title":"Pak J Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12974","article-title":"Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori","volume":"28","author":"Kwon YM","year":"2023","unstructured":"Kwon YM, Kim SJ, Lee JG, Lee SP. Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori. Helicobacter. 2023, 28:e12974. 10.1111\/hel.12974","journal-title":"Helicobacter"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/life12122038","article-title":"Helicobacter pylori: a review of current treatment options in clinical practice","volume":"12","author":"Roberts LT","year":"2022","unstructured":"Roberts LT, Issa PP, Sinnathamby ES, et al.. Helicobacter pylori: a review of current treatment options in clinical practice. Life (Basel). 2022, 12:2038. 10.3390\/life12122038","journal-title":"Life (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S386082","article-title":"Helicobacter pylori antibiotic resistance in Egypt: a single-center study","volume":"15","author":"Metwally M","year":"2022","unstructured":"Metwally M, Ragab R, Abdel Hamid HS, Emara N, Elkholy H. Helicobacter pylori antibiotic resistance in Egypt: a single-center study. Infect Drug Resist. 2022, 15:5905-13. 10.2147\/IDR.S386082","journal-title":"Infect Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10091058","article-title":"Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg)","volume":"10","author":"Bujanda L","year":"2021","unstructured":"Bujanda L, Nyssen OP, Vaira D, et al.. Antibiotic resistance prevalence and trends in patients infected with Helicobacter pylori in the period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel). 2021, 10:1058. 10.3390\/antibiotics10091058","journal-title":"Antibiotics (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293734-comparative-efficacy-of-azithromycin-and-clarithromycin-in-the-management-of-helicobacter-pylori-infection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:24:04Z","timestamp":1729524244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293734-comparative-efficacy-of-azithromycin-and-clarithromycin-in-the-management-of-helicobacter-pylori-infection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.72033","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,21]]}}}